MV Capital Management’s Viking Therapeutics VKTX Stock Holding History

MV Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3K	Buy	77 +22	+40%	+$711	﹤0.01%	728
2026 Q1	$1.79K	Hold	55	–	–	﹤0.01%	768
2025 Q4	$1.94K	Hold	55	–	–	﹤0.01%	728
2025 Q3	$1.45K	Sell	55 -3	-5%	-$89	﹤0.01%	744
2025 Q2	$1.54K	Buy	58 +44	+314%	+$1.16K	﹤0.01%	732
2025 Q1	$339	Buy	14 +6	+75%	+$190	﹤0.01%	860
2024 Q4	$322	Buy	+8	New	+$456	﹤0.01%	862

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

MV Capital Management's VKTX Position: Q2 2026 in Review

MV Capital Management increased its Viking Therapeutics (VKTX) stake by 40% in Q2 2026, buying an estimated $711 and bringing the position to 77 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #728.

MV Capital Management first reported a position in VKTX in Q4 2024 and has held it in 7 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

MV Capital Management held 77 shares of Viking Therapeutics worth $3K as of Q2 2026.
MV Capital Management bought 22 Viking Therapeutics shares in Q2 2026, an estimated $711.
Viking Therapeutics made up ﹤0.01% of MV Capital Management's portfolio in Q2 2026, its #728 holding.
MV Capital Management first reported a position in Viking Therapeutics in Q4 2024 and has held it in 7 quarters since.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.